Abstract
Pharmacologic thrombolysis is dependent on activation of endogenous plasminogen to the active proteolytic enzyme, plasmin. Agents such as tissue-plasminogen activator with a high affinity for fibrin bound plasminogen result in high local concentration of plasmin. Thus, they achieve clot lysis with less tendency to induce a systemic lytic state reflecting extensive fibrinogenolytic activity in the circulation. Appropriate dose regimens for thrombolytic agents in specific clinical situations is critical to maximize therapeutic efficacy while minimizing the risk of significant bleeding.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
